{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:26:58Z","timestamp":1790098018599,"version":"4.0.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Adult T-cell leukemia\/lymphoma (ATLL) is a rare and aggressive malignancy of mature T-cells caused by chronic infection with Human T-cell Leukemia Virus Type 1 (HTLV-1). Despite advances in understanding its pathobiology, ATLL remains associated with poor clinical outcomes, largely due to intrinsic chemoresistance and immune evasion mechanisms driven by viral oncogenes and acquired genetic alterations. The discovery of frequent mutations in TCR\/NF-\u03baB, JAK\/STAT, and apoptotic pathways has unveiled novel therapeutic vulnerabilities, while agents such as mogamulizumab have demonstrated clinical efficacy in relapsed settings. Antiviral therapies and allogeneic hematopoietic stem cell transplantation (allo-HSCT) represent pillars of treatment for selected patients, but durable remissions remain rare. This review comprehensively summarizes the molecular underpinnings of ATLL, highlights the evolving therapeutic landscape, and discusses emerging research directions aimed at improving patient outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2026.1794939","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:21Z","timestamp":1774935141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Adult T-cell leukemia\/lymphoma: molecular pathogenesis, emerging therapies, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Youssef","family":"Samaha","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, NYC Health +Hospitals\/Elmhurst","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hugo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, NYC Health +Hospitals\/Elmhurst","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Asrani","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Icahn School of Medicine at Mount Sinai","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation\/characterization of HTLV","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B2","first-page":"2755","article-title":"Proviral integration site analysis","volume":"97","author":"Takemoto","year":"2001","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological Aspects and World Distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.20144","article-title":"Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia\/lymphoma in asymptomatic carriers","volume":"110","author":"Okayama","year":"2004","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan","volume":"116","author":"Iwanaga","year":"2010","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult Tcell leukaemia-lymphoma","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/onc.2013.45","article-title":"HTLV-1 Tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation","volume":"33","author":"Choi","year":"2014","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1182\/blood-2008-04-154286","article-title":"Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation","volume":"112","author":"Arnold","year":"2008","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v8060171","article-title":"Transcriptional and epigenetic regulatory mechanisms affecting HTLV-1 provirus","volume":"8","author":"Miyazato","year":"2016","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cellleukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","article-title":"Natural history & therapy approaches (review\u2014use mainly for framing)","volume":"24","author":"Taylor","year":"2005","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00999","article-title":"Mother-to-child transmission","volume":"10","author":"Rosadas","year":"2019","journal-title":"Front Microbiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E1269","DOI":"10.1073\/pnas.1715724115","article-title":"Sporadic on\/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells","volume":"115","author":"Mahgoub","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1128\/MCB.20.10.3377-3386.2000","article-title":"Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-\u03baB pathway and is dependent on p53 phosphorylation","volume":"20","author":"Pise-Masison","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-64","article-title":"Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms","volume":"2","author":"Taniguchi","year":"2005","journal-title":"Retrovirology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","article-title":"Polycomb-mediated loss of miR-31 activates NIK-dependent NF-\u03baB pathway in adult T cell leukemia and other cancers","volume":"21","author":"Yamagishi","year":"2012","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2015-10-676452","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001274","article-title":"HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo","volume":"7","author":"Satou","year":"2011","journal-title":"PLoS Pathog"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W","article-title":"Central nervous system involvement in adult T-cell leukemia\/lymphoma","volume":"65","author":"Teshima","year":"1990","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0145-2126(93)90061-O","article-title":"Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia\/lymphoma","volume":"17","author":"Tsukasaki","year":"1993","journal-title":"Leuk Res"},{"key":"B32","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/ijc.20067","article-title":"Identifying progression-associated genes in adult T-cell leukemia\/lymphoma by using oligonucleotide microarrays","volume":"109","author":"Tsukasaki","year":"2004","journal-title":"Int J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.canlet.2005.03.039","article-title":"Impact of p53 aberration on the progression of adult T-cell leukemia\/lymphoma","volume":"234","author":"Tawara","year":"2006","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.3109\/10428194.2014.1003559","article-title":"Point mutations in TP53 but not in p15(Ink4b) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia\/lymphoma","volume":"56","author":"Magalh\u00e3es","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2017.01.002","article-title":"Allo-HSCT outcomes in Japan","volume":"23","author":"Ogata","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"51981","DOI":"10.18632\/oncotarget.10223","article-title":"Adult T-cell leukemia\/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy","volume":"7","author":"Zell","year":"2016","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"B40","volume-title":"NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas. Version 1.2024","year":"2024"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1182\/blood-2021-151238","article-title":"EPOCH Is a Safe and Effective Treatment Option for Aggressive T-CellLymphomas","volume":"138","author":"Sethi","year":"2021","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02235","article-title":"Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"Front Microbiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.13249","article-title":"Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice","volume":"108","author":"Sekine","year":"2017","journal-title":"Cancer Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2017.184564","article-title":"Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Fuji","year":"2018","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/0008-5472.CAN-03-1452","article-title":"Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation","volume":"64","author":"Harashima","year":"2004","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/bmt.2016.313","article-title":"Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia\/lymphoma, a Japanese nation-wide study","volume":"52","author":"Fujiwara","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2 study of the efficacy and safety of arsenic trioxide, interferon alfa, and zidovudine combination in patients with chronic adult T-cell leukemia\/lymphoma","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia\/Lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/10428194.2020.1852472","article-title":"Long-term responders to lenalidomide in relapsed\/recurrent adult T-cell leukemia\/lymphoma","volume":"62","author":"Goto","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lrr.2019.04.001","article-title":"Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy","volume":"11","author":"Oka","year":"2019","journal-title":"Leuk Res Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:22Z","timestamp":1774935142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":60,"alternative-id":["10.3389\/fonc.2026.1794939"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1794939","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1794939"}}